Scinai Immunotherapeutics (SCNI) EBITDA Margin (2024 - 2026)

Scinai Immunotherapeutics has disclosed EBITDA Margin across 3 years of filings, most recently posting 466.52% for Q2 2026.

• In Q2 2026, EBITDA Margin rose 70728.0% year-over-year to 466.52%; the TTM figure through Jun 2026 stood at 486.41% (up 24994.0% YoY), while the FY2025 annual figure was 407.91%, up 90485.0% from the prior year.
• EBITDA Margin came in at 466.52% for Q2 2026 at Scinai Immunotherapeutics, up from 504.5% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 267.58% in Q1 2025 to a low of 1440.48% in Q3 2024.
• Average EBITDA Margin over 3 years is 825.24%, with a median of 801.52% recorded in 2026.
• The largest YoY upside for EBITDA Margin was 70728 bps in 2026 against a maximum downside of 23692 bps in 2026.
• Over 3 years, EBITDA Margin stood at 1098.54% in 2024, then decreased by 7 bps to 1173.8% in 2025, then surged by 60 bps to 466.52% in 2026.
• Per Business Quant data, the three most recent EBITDA Margin figures were 466.52% in Q2 2026, 504.5% in Q1 2026, and 1173.8% in Q2 2025.